Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors
Conclusions: Overall, there was no difference in PFS between octreotide LAR and somatuline depot for pts with well-differentiated, metastatic GEP-NETs. A prospective study is worth designing selecting for G.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer & Oncology | Gastroenterology | Neurology | Pancreas | Sandostatin | Statistics | Study